GlassScriptPhysician profile
Stanford C Rapp
NPI 1427038165
$9,711.09
in general payments reported to CMS, 2019-2025
48 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $751 · 2021: $1,529 · 2022: $1,440 · 2023: $1,178 · 2024: $1,860 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,886.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,449.52 | 2021-2025 | Nayzilam, Briviact, Rystiggo |
| Abbvie INC. | $1,169.40 | 2021-2025 | |
| Lilly USA, LLC | $738.65 | 2019-2024 | Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $718.17 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sk Life Science, INC. | $676.38 | 2020-2025 | |
| Pfizer INC. | $461.38 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $453.55 | 2019-2022 | |
| Neurelis, INC. | $392.13 | 2020-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $360.12 | 2020-2024 | Ingrezza, Ongentys |
| Argenx US, INC. | $290.70 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $284.18 | 2019-2020 | |
| Amgen INC. | $208.19 | 2019-2022 | |
| Acorda Therapeutics, INC | $206.40 | 2019-2020 | |
| Aucta Pharmaceuticals, INC. | $202.74 | 2024-2025 | Motpoly Xr |
| Genentech USA, INC. | $186.52 | 2019-2025 | Ocrevus Zunovo |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanford Rapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.